|
US4237224A
(en)
|
1974-11-04 |
1980-12-02 |
Board Of Trustees Of The Leland Stanford Jr. University |
Process for producing biologically functional molecular chimeras
|
|
US6022950A
(en)
|
1984-06-07 |
2000-02-08 |
Seragen, Inc. |
Hybrid molecules having translocation region and cell-binding region
|
|
GB8516442D0
(en)
|
1985-06-28 |
1985-07-31 |
Wellcome Found |
Cloned antigen
|
|
US5919665A
(en)
|
1989-10-31 |
1999-07-06 |
Ophidian Pharmaceuticals, Inc. |
Vaccine for clostridium botulinum neurotoxin
|
|
US7037680B2
(en)
|
1993-09-21 |
2006-05-02 |
The United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
US7227010B2
(en)
|
1993-09-21 |
2007-06-05 |
United States Of America As Represented By The Secretary Of The Army |
Recombinant light chains of botulinum neurotoxins and light chain fusion proteins for use in research and clinical therapy
|
|
CA2191754C
(en)
|
1994-05-31 |
2000-12-12 |
James Oliver Dolly |
Modification of clostridial toxins for use as transport proteins
|
|
WO1996005222A1
(en)
|
1994-08-08 |
1996-02-22 |
Wisconsin Alumni Research Foundation |
Purification and pharmaceutical compositions containing type g botulinum neurotoxin
|
|
US6967088B1
(en)
|
1995-03-16 |
2005-11-22 |
Allergan, Inc. |
Soluble recombinant botulinum toxin proteins
|
|
GB9508204D0
(en)
|
1995-04-21 |
1995-06-07 |
Speywood Lab Ltd |
A novel agent able to modify peripheral afferent function
|
|
US5792462A
(en)
|
1995-05-23 |
1998-08-11 |
University Of North Carolina At Chapel Hill |
Alphavirus RNA replicon systems
|
|
CA2252439C
(en)
|
1996-04-19 |
2014-09-30 |
Henry M. Jackson Foundation For The Advancement Of Military Medicine |
Method of stimulating an immune response by administration of host organisms that express intimin alone or as a fusion protein with one or more other antigens
|
|
US5750383A
(en)
|
1996-05-14 |
1998-05-12 |
Boyce Thompson Institute For Plant Research, Inc. |
Baculovirus cloning system
|
|
GB9617671D0
(en)
|
1996-08-23 |
1996-10-02 |
Microbiological Res Authority |
Recombinant toxin fragments
|
|
US7192596B2
(en)
|
1996-08-23 |
2007-03-20 |
The Health Protection Agency Ipsen Limited |
Recombinant toxin fragments
|
|
US5939070A
(en)
|
1996-10-28 |
1999-08-17 |
Wisconsin Alumni Research Foundation |
Hybrid botulinal neurotoxins
|
|
US6001806A
(en)
|
1997-06-27 |
1999-12-14 |
Humn Genome Sciences, Inc. |
Interferon stimulating protein and uses thereof
|
|
US6037150A
(en)
|
1997-08-21 |
2000-03-14 |
University Technologies International Inc. |
Insect sequences for improving the efficiency of secretion of non-secreted proteins in eukaryotic cells
|
|
US6051239A
(en)
|
1997-10-20 |
2000-04-18 |
Thomas Jefferson University |
Compositions and methods for systemic delivery of oral vaccines and therapeutic agents
|
|
US6323023B1
(en)
|
1998-01-13 |
2001-11-27 |
Yissum Research Development Co., Ltd. |
Vectors containing nucleic acids coding for Arabidopsis thaliana endo-1,4-β-glucanase secretion signal peptide
|
|
US20040071736A1
(en)
|
1998-08-25 |
2004-04-15 |
Health Protection Agency |
Methods and compounds for the treatment of mucus hypersecretion
|
|
JP2003508092A
(ja)
|
1999-08-20 |
2003-03-04 |
インペリアル・カレッジ・イノベイションズ・リミテッド |
細胞エキソサイトーシスの調節におけるｓｎａｒｅ分子のイソフォーム及びその使用
|
|
BR0012759A
(pt)
|
1999-08-25 |
2002-04-02 |
Allergan Sales Inc |
Neurotoxinas recombinantes ativáveis
|
|
AU2001271614B2
(en)
|
2000-07-03 |
2007-05-31 |
Catalent Pharma Solutions, Llc |
Host cells containing multiple integrating vectors
|
|
WO2002002783A2
(en)
|
2000-07-03 |
2002-01-10 |
Gala Design, Inc. |
Expression vectors
|
|
US6903187B1
(en)
|
2000-07-21 |
2005-06-07 |
Allergan, Inc. |
Leucine-based motif and clostridial neurotoxins
|
|
US7691983B2
(en)
|
2000-07-21 |
2010-04-06 |
Allergan, Inc. |
Chimera botulinum toxin type E
|
|
US7491799B2
(en)
|
2000-07-21 |
2009-02-17 |
Allergan, Inc. |
Modified botulinum neurotoxins
|
|
US6831059B2
(en)
|
2000-10-20 |
2004-12-14 |
Allergan, Inc. |
Compositions and methods for treating gonadotrophin related illnesses
|
|
EP1358207A4
(en)
|
2000-11-15 |
2004-07-21 |
Us Gov Health & Human Serv |
REFUSION: USE OF GP64-6HIS TO CATALYZE MEMBRANE FUSION
|
|
US7223577B2
(en)
|
2000-11-17 |
2007-05-29 |
Allergan, Inc. |
Post-translational modifications and Clostridial neurotoxins
|
|
US7273722B2
(en)
|
2000-11-29 |
2007-09-25 |
Allergan, Inc. |
Neurotoxins with enhanced target specificity
|
|
US7255865B2
(en)
|
2000-12-05 |
2007-08-14 |
Allergan, Inc. |
Methods of administering botulinum toxin
|
|
US6787517B1
(en)
|
2000-12-29 |
2004-09-07 |
Allergan, Inc. |
Agent and methods for treating pain
|
|
WO2002060936A2
(en)
|
2001-01-31 |
2002-08-08 |
University Of Iowa Research Foundation |
Vaccine and compositions for the prevention and treatment of neisserial infections
|
|
US7332567B2
(en)
|
2001-08-28 |
2008-02-19 |
Allergan, Inc. |
Fret protease assays for clostridial toxins
|
|
EP1334729A1
(en)
*
|
2002-02-07 |
2003-08-13 |
Botulinum Toxin Research Associates, Inc. |
Therapeutic use of non-neurotoxic clostridium botulinum toxin type C2
|
|
CN101044154A
(zh)
|
2002-02-14 |
2007-09-26 |
威廉·J·鲁特 |
治疗宿主中切割的嵌合分子
|
|
US20040101531A1
(en)
|
2002-04-16 |
2004-05-27 |
Roy Curtiss |
Immunogenic compositions and vaccines comprising carrier bacteria that secrete antigens
|
|
WO2004040398A2
(en)
|
2002-05-06 |
2004-05-13 |
Dana-Farber Cancer Institute, Inc. |
Use of a computer to design a molecule
|
|
NZ537120A
(en)
|
2002-05-31 |
2008-07-31 |
Univ Jefferson |
Compositions and methods for transepithelial molecular transport
|
|
US20040018589A1
(en)
|
2002-07-25 |
2004-01-29 |
Jun Zhong |
Method for producing biologically active botulinum neurotoxins through recombinant DNA technique
|
|
US20040115727A1
(en)
|
2002-12-11 |
2004-06-17 |
Allergan, Inc., A Corporation |
Evolved clostridial toxins with altered protease specificity
|
|
US7172764B2
(en)
|
2003-11-17 |
2007-02-06 |
Allergan, Inc. |
Rescue agents for treating botulinum toxin intoxications
|
|
AU2005274822B2
(en)
|
2004-07-26 |
2008-10-30 |
Merz Pharma Gmbh & Co. Kgaa |
Therapeutic composition with a botulinum neurotoxin
|
|
US20060024794A1
(en)
|
2004-07-30 |
2006-02-02 |
Shengwen Li |
Novel methods for production of di-chain botulinum toxin
|
|
WO2006017749A2
(en)
|
2004-08-04 |
2006-02-16 |
Allergan, Inc. |
Optimizing expression of active botulinum toxin type a
|
|
US7199193B2
(en)
|
2004-09-28 |
2007-04-03 |
Dow Global Technologies, Inc. |
Polyethylene glycol compounds and process of making
|
|
EP1824971B1
(en)
*
|
2004-11-22 |
2016-01-13 |
New York University |
Genetically engineered clostridial genes, proteins encoded by the engineered genes, and uses thereof
|
|
US8512984B2
(en)
|
2004-12-01 |
2013-08-20 |
Syntaxin, Ltd. |
Non-cytotoxic protein conjugates
|
|
GB0426394D0
(en)
|
2004-12-01 |
2005-01-05 |
Health Prot Agency |
Fusion proteins
|
|
GB0610867D0
(en)
*
|
2006-06-01 |
2006-07-12 |
Syntaxin Ltd |
Treatment of pain
|
|
TWI332851B
(en)
|
2007-04-27 |
2010-11-11 |
Dermato Plastica Beauty Dpb Co Ltd |
Volume adjustable, micro-injection device
|
|
US8586081B2
(en)
|
2007-09-20 |
2013-11-19 |
University Of Massachusetts |
Detoxified recombinant botulinum neurotoxin
|
|
US9044477B2
(en)
|
2007-12-12 |
2015-06-02 |
Allergan, Inc. |
Botulinum toxin formulation
|
|
US8796216B2
(en)
|
2008-06-12 |
2014-08-05 |
Syntaxin Limited |
Suppression of neuroendocrine diseases
|
|
GB0903006D0
(en)
*
|
2009-02-23 |
2009-04-08 |
Syntaxin Ltd |
Modified non-cytotoxic proteases
|
|
EP2528941A4
(en)
|
2010-01-25 |
2013-05-29 |
Univ New York |
FOR TRANSPORT STUDIES AND NEURONAL ADMINISTRATION, MANIPULATED RECOMBINANT DERIVATIVES FROM BOTULINUM NEUROTOXINES
|
|
DK2948174T3
(da)
*
|
2013-01-28 |
2019-12-02 |
Univ New York |
Fremgangsmåder til behandling under anvendelse af atoksiske neurotoksinderivater
|